
Medpace, a leading global Clinical Research Organization (CRO) headquartered in Cincinnati, USA, has announced openings for full-time, office-based Drug Safety Specialists / Clinical Safety Coordinators at its India office in Navi Mumbai.
This position within the Clinical Safety department focuses on end-to-end case processing and adverse event handling from clinical trials through post-marketing surveillance.
Key Job Details
- Job Title: Drug Safety Specialist / Clinical Safety Coordinator
- Company: Medpace
- Location: Navi Mumbai, India
- Work Mode: Full-time, Office-based
- Industry Type: Pharma / Healthcare / Clinical Research
- Functional Area: Clinical Safety / Pharmacovigilance
- Application Deadline: 21 October 2026
Core Responsibilities
- Manage incoming safety-related queries and determine clear action plans for incoming calls.
- Collect, track, verify, and process incoming adverse events (AEs) and serious adverse events (SAEs) from clinical trials and post-marketing sources.
- Draft accurate and compliant safety narratives.
- Compile and report on structured clinical safety and pharmacovigilance data.
- Liaise directly with investigative clinical study sites and cross-functional teams to maintain strict safety compliance and follow standard operating procedures.
Candidate Profile & Eligibility
- Education: Bachelor’s degree in a healthcare-related field (B.Pharm, Pharm.D, Pharmacology, Nursing, or related life sciences).
- Experience: Prior background in clinical safety, case processing, clinical research operations, or post-marketing pharmacovigilance (PV) is preferred.
- Skill Set:
- Strong working command of English (both written and verbal).
- In-depth understanding of medical terminology and adverse event nomenclature.
- Proficiency in Microsoft Office tools.
- High organizational accuracy and effective multi-department communication skills.
How to Apply
Interested candidates meeting the criteria should submit their application through the official Medpace careers portal before the closing deadline on 21 October 2026.
